Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.49 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.48 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11305715 | 0.83 | TSHR (0.69) | TSHRTRPV1SMN1; SMN2LMNATP53 | |
| SCHEMBL2260845 | 0.82 | MCL1 (0.70) | MCL1SMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL4035255 | 0.80 | TSHR (0.65) | TSHRTRPV1SMN1; SMN2LMNATP53 | |
| SCHEMBL31248395 | 0.80 | TSHR (0.65) | TSHRTRPV1SMN1; SMN2LMNATP53 | |
| SCHEMBL13683247 | 0.80 | TSHR (0.65) | TSHRTRPV1SMN1; SMN2LMNATP53 | |
| SCHEMBL6315764 | 0.80 | MCL1 (0.67) | MCL1ALDH1A1KMT2AHTTP2RX7 | |
| SCHEMBL3436878 | 0.79 | MCL1 (0.61) | MCL1TRPV1 | |
| SCHEMBL19204669 | 0.79 | TSHR (0.51) | TSHRTRPV1SMN1; SMN2LMNATP53 | |
| SCHEMBL6361222 | 0.79 | TSHR (0.68) | TSHRTRPV1SMN1; SMN2LMNATP53 | |
| SCHEMBL7937579 | 0.79 | TSHR (0.63) | TSHRTRPV1SMN1; SMN2LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998986-B2 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998986-B2 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20030181420-A1 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS, INC. | 2003-09-25 | — | — | US | disclosed |
| US-4104273-A | Derivatives of 3-cyano-pyrid-2-ones | ROHM AND HAAS COMPANY (US) | 1978-08-01 | — | — | US | disclosed |
| US-4028084-A | Derivatives of 3-carboxy pyrid-2-ones | ROHM AND HAAS COMPANY (US) | 1977-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181420-A1 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | NR1H2, NR1H3, NCOA1 | MCL1 3083/4885TSHR 471/4885TRPV1 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.